As kinesins are relatively difficult to target pharmaceutically, and complete inhibition of KIFC1 may have non-cancer cell specific effects (Xiao and Yang, 2016), targeting OTUD6B has the potential to be developed as a more tolerable therapeutic route. Here, KIFC1 is linked to cancer.